Impact of Pharmacogenomic Testing in Pediatric Heart and Kidney Transplant
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Rachel L Jackson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Primary Children's Hospital, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Heart Transplantation, Pharmacogenomic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Center for Personalized Medicine, PCH.
Abstract (Originalsprache)
Background
Pediatric solid organ transplantation is a complex process including a tightly orchestrated medication regimen, essential for prevention of infection, rejection, graft failure, and mortality. Pharmacogenomic (PGx) testing tailors medication therapy to the individual patient, focusing on safety, efficacy, and avoidance of adverse effects. Implementation of PGx panel results into clinical practice for pediatric transplant patients has not been evaluated.
Methods
Pediatric patients evaluated for heart, kidney, or combined heart‐kidney transplant at a tertiary children's hospital from October 2021 to October 2023 received PGx panel testing. Primary outcome measure: Report the prevalence of actionable PGx variants for key genes impacting pharmacotherapy in pre‐ and post–heart and kidney transplant populations.
Results
A total of 73 patients were included, predominately white (84.9%) and male (64.4%), with a mean age of 8.8 ± 6.4 years. Indications for PGx testing included evaluation for heart transplant (38.4%), kidney transplant (38.4%), combined heart–kidney transplant (4.1%), or to inform posttransplant care (19.2%). All patients had at least one actionable phenotype identified. 37 of 73 patients (50.7%) had at least one actionable phenotype for the transplant‐specific genes captured including CYP3A5 , SLCO1B1, G6PD, TPMT , prothrombin (Factor 2), and Factor V Leiden. 16 of 73 patients (21.9%) had actionable CYP3A5 phenotypes. 15 of 73 (20.5%) had actionable SLCO1B1 phenotypes. 9 of 73 patients (12.3%) had actionable TPMT phenotypes. 5 of 73 (6.8%) had Prothrombin or Factor V Leiden variants.
Conclusions
Routine pretransplant PGx testing provided information that was actionable and could be utilized to optimize posttransplant medications for all patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Primary Children's Hospital, Salt Lake City, Utah, USA.
- Division of Nephrology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
- Division of Cardiology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
- Division of Pediatric Neurology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
- Center for Personalized Medicine, Primary Children's Hospital, Salt Lake City, Utah, USA.
ORCID-Profile: Rachel L Jackson, Caroline Heyrend, Caitlin Peterson, Lindsay J May, Joshua L Bonkowsky
Förderung
- Center for Personalized Medicine, PCH
Zitieren
APA
Jackson, R. L., Heyrend, C., Bucher, B., Brewer, A., Peterson, C., May, L. J., & Bonkowsky, J. L. (2025). Impact of Pharmacogenomic Testing in Pediatric Heart and Kidney Transplant. Pediatric Transplantation. https://doi.org/10.1111/petr.70044
Vancouver
Jackson RL, Heyrend C, Bucher B, Brewer A, Peterson C, May LJ, et al. Impact of Pharmacogenomic Testing in Pediatric Heart and Kidney Transplant. Pediatric Transplantation. 2025. doi:10.1111/petr.70044
BibTeX
@article{Jackson2025,
author = {Jackson, Rachel L and Heyrend, Caroline and Bucher, Bridget and Brewer, Ashlie and Peterson, Caitlin and May, Lindsay J and Bonkowsky, Joshua L},
title = {Impact of Pharmacogenomic Testing in Pediatric Heart and Kidney Transplant},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70044}
}
EUVIMED